Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

  • The European Commission (EC) has granted conditional approval to Incyte Corporation INCYMorphoSys AG's MOR Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT). 
  • The conditional approval is based on the results from the L-MIND study that showed the best objective response rate (ORR) of 56.8% (primary endpoint), including a complete response (CR) rate of 39.5% and a partial response rate (PR) of 17.3%. 
  • Incyte has exclusive commercialization rights to tafasitamab outside the U.S. 
  • Related content: Benzinga's Full FDA Calendar
  • Price Action: MOR shares traded 1.27% higher at $14.31 premarket Friday, and Incy shares closed 0.81% lower at $75.15 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsDiffuse Large B-Cell Lyphoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!